The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer.
 
Steven H. Lin
Honoraria - AstraZeneca/MedImmune
Speakers' Bureau - Varian Medical Systems
Research Funding - Genentech/Roche; Hitachi Chemical; New River Labs; STCube Pharmaceuticals Inc.
 
Yan Lin
No Relationships to Disclose
 
Isabel Mok
No Relationships to Disclose
 
Jenean A. Young
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
See Phan
Employment - Genentech/Roche
Leadership - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Honoraria - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Alan Sandler
Employment - Genentech/Roche
Leadership - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Honoraria - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Abbvie; Araxes Pharma; ARIAD; Arrys Therapeutics; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech; Genentech; Gritstone Bio; Janssen; Lilly; Loxo; Merck; Nektar; Novartis; Pfizer; Takeda; Tesaro; TRM Oncology
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Roche
Other Relationship - Roche
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Merck; Novartis; Spectrum Pharmaceuticals
Research Funding - AstraZeneca (Inst); Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Anne S. Tsao
Consulting or Advisory Role - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Epizyme; Genentech/Roche; HERON; Imedex; Lilly; MedImmune; Novartis; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); MedImmune (Inst); Merck (Inst); Millennium; Polaris; Seagen
Patents, Royalties, Other Intellectual Property - UptoDate